相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
David C. Grossman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Tokhir Dadaev et al.
NATURE COMMUNICATIONS (2018)
Polygenic hazard score to guide screening for aggressive - prostate cancer: development and validation in large scale - cohorts
Tyler M. Seibert et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Polygenic hazard score to guide screening for aggressive - prostate cancer: development and validation in large scale - cohorts
Tyler M. Seibert et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer A Life-Table Model
Nora Pashayan et al.
JAMA ONCOLOGY (2018)
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
Dragan Ilic et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Marco Matejcic et al.
NATURE COMMUNICATIONS (2018)
Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms
Roman Gulati et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
F. C. Hamdy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
Joanna C. Thorn et al.
BMJ OPEN (2016)
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
Joshua A. Roth et al.
JAMA ONCOLOGY (2016)
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis
Nora Pashayan et al.
GENETICS IN MEDICINE (2015)
Estimating the cost of caring for people with cancer at the end of life: A modelling study
Jeff Round et al.
PALLIATIVE MEDICINE (2015)
Decomposing socio-economic inequality in colorectal cancer screening uptake in England
Francesca Solmi et al.
SOCIAL SCIENCE & MEDICINE (2015)
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schroder et al.
LANCET (2014)
The genetic epidemiology of prostate cancer and its clinical implications
Rosalind Eeles et al.
NATURE REVIEWS UROLOGY (2014)
Public health implications from COGS and potential for risk stratification and screening
Hilary Burton et al.
NATURE GENETICS (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
VALUE IN HEALTH (2013)
Quality-of-Life Effects of Prostate-Specific Antigen Screening
Eveline A. M. Heijnsdijk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England
Christian von Wagner et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2011)
Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available
Roberta Ara et al.
VALUE IN HEALTH (2011)
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
N. Pashayan et al.
BRITISH JOURNAL OF CANCER (2009)
Polygenic susceptibility to breast cancer and implications for prevention
PDP Pharoah et al.
NATURE GENETICS (2002)
分享论文
